Updated
Updated · Singularity Hub · Jul 28
David Liu Team Redesigns Botox Enzyme With AI, Boosting ALS-Linked Protein Cutting 80-Fold
Updated
Updated · Singularity Hub · Jul 28

David Liu Team Redesigns Botox Enzyme With AI, Boosting ALS-Linked Protein Cutting 80-Fold

1 articles · Updated · Singularity Hub · Jul 28

Summary

  • ProteinMPNN-generated Botox-enzyme variants gave David Liu’s team a stronger starting point for directed evolution, producing enzymes that cut an ALS-linked protein nearly 80 times more efficiently and 56 times more selectively than versions evolved from natural enzymes.
  • 58 AI designs were screened and the top three proved highly soluble and sometimes more active in E. coli, addressing a core problem in enzyme engineering: natural starting proteins often destabilize and fail as mutations accumulate.
  • The team then ran the redesigned enzymes through PACE—Liu’s rapid evolution system—to retarget botulinum neurotoxin proteases toward a mutant region of a neuron-related protein that can clump and damage cells in ALS.
  • Tests were limited to immortalized human cells, so performance in more complex biological settings is still unproven, but the work suggests AI-stabilized proteins could widen the range of designer enzymes beyond what natural templates allow.

Insights

Could a deadly toxin redesigned by AI become the ultimate cure for neurodegenerative diseases like ALS?
What happens when artificial intelligence turns the world's most potent neurotoxin into a highly precise medical scalpel?